Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial

OBJECTIVE: To assess non-inferiority of s.c. to i.v. CT-P13 in RA. METHODS: Patients with active RA and inadequate response to MTX participated in this phase I/III double-blind study at 76 sites. Patients received CT-P13 i.v. 3 mg/kg [week (W) 0 and W2] before randomization (1:1) at W6 to CT-P13 s.c...

Descripción completa

Detalles Bibliográficos
Autores principales: Westhovens, Rene, Wiland, Piotr, Zawadzki, Marek, Ivanova, Delina, Kasay, Alfredo Berrocal, El-Khouri, Elias Chalouhi, Balázs, Éva, Shevchuk, Sergii, Eliseeva, Larisa, Stanislavchuk, Mykola, Yatsyshyn, Roman, Hrycaj, Paweł, Jaworski, Janusz, Zhdan, Vyacheslav, Trefler, Jakub, Shesternya, Pavel, Lee, Sang Joon, Kim, Sung Hyun, Suh, Jee Hye, Lee, Seul Gi, Han, Noo Ri, Yoo, Dae Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121438/
https://www.ncbi.nlm.nih.gov/pubmed/33230526
http://dx.doi.org/10.1093/rheumatology/keaa580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121438/
https://www.ncbi.nlm.nih.gov/pubmed/33230526
http://dx.doi.org/10.1093/rheumatology/keaa580

Ejemplares similares